NAD+: The Shuttle They're Selling You
It's the most important molecule in cellular metabolism you've never heard of. It also sits at the center of a $1B/year supplement industry built on extrapolating mouse results to humans.
A molecule that moves electrons
Every second your cells are alive, they are running a chemical reaction called respiration — pulling electrons off the glucose and fats you ate, sliding those electrons down an energetic staircase, and capturing the energy at each step as ATP. Without this, you stop functioning in about 30 seconds.
The molecule that physically carries those electrons from the food to the staircase is nicotinamide adenine dinucleotide, or NAD+ for short.
A single NAD+ molecule docks at an enzyme. The enzyme strips two hydrogen atoms off some food-derived substrate. One hydrogen with both electrons goes onto NAD+, becoming NADH. NADH then floats to a different enzyme and dumps its electrons into the electron transport chain — the staircase. The transport chain uses the electron’s energy to pump protons across a membrane, building up a charge gradient. ATP synthase, the molecular turbine that sits in that membrane, lets the protons flow back through and uses their force to fuse ADP with phosphate to make ATP.
This cycle runs millions of times per second per cell. Every gram of food you metabolize, every breath you take, every thought that fires in your brain — none of it works without NAD+ moving electrons. A 70-kg adult turns over about 9 grams of NAD+ per day.
Your blood doesn’t contain NAD+. Each cell makes its own.
How biochemistry got here
NAD+ was first isolated in 1906 by Arthur Harden and William Young, who were studying fermentation in yeast and noticed a small cofactor that bound to enzymes and seemed to be required for the reaction to proceed. They called it cozymase. Harden shared the 1929 Nobel with Hans von Euler-Chelpin, whose structural work pinned down what cozymase actually was.
Otto Warburg, in the 1930s, identified that the active piece of cozymase was a nicotinamide ring derived from vitamin B3. Nicotinamide deficiency — the disease pellagra — had been killing southern Americans by the tens of thousands annually until Joseph Goldberger, working for the US Public Health Service, demonstrated it was a dietary problem and not infectious. Goldberger went so far as to inject himself, his wife, and his colleagues with material from pellagra patients to prove the disease wasn’t contagious. None of them got sick. (Vitamin B3 was added to enriched flour in 1938; pellagra essentially disappeared from the US within a decade.)
So by the 1940s, the picture was: nicotinamide (vitamin B3) → built into NAD+ → which carries electrons → which feeds the energy economy.
What nobody knew until much later is that NAD+ does several other completely separate jobs.
The second life of NAD+
In 2000, working in Leonard Guarente’s lab at MIT, biochemist Shin-ichiro Imai showed that NAD+ is also consumed by a family of enzymes called sirtuins. Sirtuins remove acetyl groups from proteins — particularly histones, the spool-like proteins around which your DNA winds — and in doing so they alter which genes are expressed. They are the cell’s “longevity” enzymes, the ones turned on by calorie restriction (the only experimentally validated lifespan-extension intervention in mammals).
Sirtuins consume NAD+ as a substrate. Every time a sirtuin removes an acetyl group, it cleaves an NAD+ molecule in the process. The NAD+ is regenerated, but slowly.
Another family of NAD+-consuming enzymes, PARPs, had been discovered way back in 1963 by Pierre Chambon; their DNA-repair role got pinned down through the 1970s–80s. Every time a PARP detects a broken DNA strand, it pulls hundreds of NAD+ molecules to tag the site.
And then CD38 — an enzyme on immune cell surfaces — was shown to consume NAD+ at very high rates during inflammation.
The picture suddenly looked like this: cellular NAD+ is a pool. It’s the substrate for electron shuttling. It’s also the substrate for longevity enzymes, DNA repair enzymes, and inflammation enzymes. When demand goes up — chronic inflammation, sustained DNA damage from aging, hyperactive sirtuins — the pool drops.
And NAD+ pool size does drop with age, though the magnitude is disputed. The popular figure cited by the supplement industry is “~50% lower by your 60s”; the largest properly controlled human blood study to date (n≈1,500) found closer to a ~14% decline, and no clear decline in women. The drop is real but smaller than the marketing implies.
A reasonable hypothesis
Cellular NAD+ drops with age. Sirtuins, which influence longevity in animal models, depend on NAD+. Therefore, raising cellular NAD+ might slow aging.
This is the hypothesis behind a billion-dollar supplement industry.
In mice, this works to a surprising degree. Feeding aged mice NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) — both precursors that cells convert to NAD+ — modestly restores cellular NAD+ levels. It improves mitochondrial function, muscle strength, glucose tolerance, and (in some experimental designs) median lifespan by 5–10%. The David Sinclair lab at Harvard has been the most visible advocate, and Sinclair himself takes NMN daily and publishes books with names like Lifespan.
In humans, the picture is far less clear. Several short clinical trials of NMN or NR (typical dose 250–1000 mg/day, typical duration 8–12 weeks) have shown that the supplements do raise circulating NAD+ metabolites. Beyond that, the data are thin. The trials that have measured downstream outcomes — insulin sensitivity, muscle function, inflammatory markers — have mostly found small, often statistically insignificant effects. The largest and longest randomized trials have not yet been published.
The honest summary as of 2027: NMN and NR raise NAD+ measurably; whether this translates into any meaningful health benefit in healthy humans is genuinely unknown. The supplement industry is selling extrapolation from mouse studies to humans, which is the same extrapolation that has failed for hundreds of other “promising” compounds in the last 50 years.
What actually raises NAD+
Three things are reasonably well-established to raise cellular NAD+ in humans, none of which involves a supplement:
- Exercise. Particularly endurance exercise. Acutely depletes NAD+, then upregulates synthesis enzymes; chronic effect is higher baseline NAD+ in muscle.
- Caloric restriction or intermittent fasting. Mechanistically tied to sirtuin activation, which (interestingly) also lowers CD38, which (interestingly) reduces NAD+ degradation. The pool rises.
- Sleep. NAD+ has a strong circadian rhythm. Disrupted sleep flattens the curve and lowers overall pool size.
You can buy these for $0. They are also, separately, the three things that show up in basically every randomized trial of human longevity. Whether the NAD+ pathway is the reason they work or just a marker of them working is an open question. But the upstream interventions are validated regardless.
A note on what NMN is doing in your body
If you currently take NMN or NR, what’s actually happening: in the intestine, most of the dose is broken down by gut bacteria and intestinal enzymes. A small fraction reaches the bloodstream as nicotinamide. Tissues take it up and rebuild it into NAD+ via a salvage pathway. Some tissues use the precursor preferentially over plain nicotinamide; muscle and liver appear to be the main beneficiaries.
You are paying ~5/month for the same number of grams) is a question the industry has every incentive not to answer cleanly.
The molecule has done its job
Three Nobel Prizes have been won for work on NAD+ (Harden 1929, Warburg 1931, Krebs 1953 — TCA cycle, where NAD+ is central). It is one of the most-studied small molecules in biology. We genuinely know what it does in your cells. The science is solid.
What’s less solid is the cultural overlay. Anti-aging is one of the largest unmet markets in medicine, the kind of unmet need that creates a powerful gravitational pull on otherwise rigorous scientists. Sinclair’s lab does real work; he also founded multiple companies selling NAD+ precursors. The conflict-of-interest disclosures on his papers are extensive. This is not corruption — it’s the modern condition of biotech-adjacent science — but it does affect how you should read the hype.
The NAD+ molecule itself is not selling you anything. It’s just doing what it has been doing for about 3.5 billion years: moving electrons from food to ATP synthase, with side jobs in DNA repair and gene expression. The cells in your body that are alive at this exact moment are processing several million NAD+ molecules per second to keep you alive. None of that depends on a supplement bottle on a shelf at CVS.
The honest pitch for NAD+ would be: “this is one of the most important molecules in your biology, almost nothing you do affects it as much as your sleep, diet, and exercise, and the supplements are mostly extrapolation.” That is, of course, not a pitch that sells $1B of NMN per year.
The NAD+ molecule has its own 3D page in the library — rotate it, find the nicotinamide ring (vitamin B3 in disguise) and the adenosine half it’s linked to, download the structure file. It also has its own bouncing wallpaper.